Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Zentalis Pharmaceuticals, Inc.

35 indications, side-by-side phase, drug & LoA

$3.75

+0.23 (+6.53%)

C 45Pipeline Score Overvalued Biotech · Clinical
Market Cap
289.02 M
EPS
-1.74
P/E Ratio
-
Value Trade
4.35 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • R&D Expenses

    28.72 M

  • Operating CF

    -32.96 M

  • Total Assets

    253.07 M

  • Total Liabilities

    70.39 M

  • Equity

    182.68 M

  • D/E Ratio

    12,345

1.5 %
Week
0.25 %
1 Month
61.75 %
3 Month
212.31 %
6 Month
-93.21 %
5 Year
-83.89 %
All Time
Cash Data
Stable

  • Cash Position

    211.76 M

  • Monthly Burn

    10.98 M

  • Runway

    18.3 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 12, 2026
Overview
Volume
889.96 K
52 Week Range
1.13 - 6.95
% held by Insiders
35.4 %
% held by Institutions
53.98 %
Enterprise Value
115.91 M
Total Shares
72.24 M
Short %
10.75 %
Float Shares
46.67 M
Company Description
HQ: 10275 SCIENCE CENTER DRIVE, SA...
Employees:106
https://www.zentalis.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout example
Azenosertib Cyclin E1+ platinum-resistant ovarian cancer (PROC)
Phase 2
—
Small Molecules
Oncology
Azenosertib Cyclin E1+ platinum-resistant ovarian cancer (PROC)
Phase 2
—
Small Molecules
Oncology
Azenosertib Cyclin E1+ platinum-resistant ovarian cancer (PROC)
Phase 2
—
Small Molecules
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C45
Pipeline Score
$79M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.3x
rNPV / MCap
Top 67%
Micro Cap
(rank 300 of 905)
Percentile Rank
Zentalis Pharmaceuticals, Inc. carries a moderate pipeline score (45/100), with $610M risk-adjusted pipeline value, led by Azenosertib in Uterine Serous Carcinoma (Phase 2), across $63B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Azenosertib
Small molecule		Uterine Serous CarcinomaPhase 2NCT0481410819% $516M COMPLETED 117 - -Oct 22, 2025 -MEDIUM
May 21, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ZNTL
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ZNTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZNTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZNTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ZNTL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ZNTL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Zentalis Pharmaceuticals, Inc. (ZNTL) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ZNTL ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Ovarian Cancer #11 of 60 PHASE 3 Azenosertib
MRK AZN LLY
$4.11B 0.88 CONTENDER